6.7% stakeholder Shah Capital proposes new directors to address Novavax's underperformance.
Shah Capital, a 6.7% stakeholder in Novavax, proposes two new directors, Suresh Katta and Venkat Peri, to the firm's board. Shah Capital has been disappointed with Novavax's performance and underperformance, with the company's share price near an all-time low and one of the most shorted stocks on Nasdaq. The investment firm believes the new directors will bring needed expertise to address these issues.
April 15, 2024
3 Articles